Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine genomic database.
Authors
Dustin A. Deming
University of Wisconsin Carbone Cancer Center, Madison, WI
Dustin A. Deming , Norma Alonzo Palma , Willis H. Navarro , Gopa Iyer , David J. Kwiatkowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 558)
DOI
10.1200/JCO.2024.42.3_suppl.558
Abstract #
558
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database.
First Author: Gopa Iyer
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The genomic landscape of patients with advanced colorectal adenocarcinoma with PIK3CA mutations using comprehensive cell free tumor DNA next generation sequencing.
First Author: Nilesh Verma
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in advanced pancreatic neuroendocrine neoplasms (PanNENs).
First Author: Darren Cowzer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The genomic landscape of advanced gastrointestinal (GI) neuroendocrine tumors (NET) and carcinomas (NEC).
First Author: Nicole Farha